Clinical Presentation and Successful Management of an Infant With Down Syndrome and COVID-19 in Riyadh, Saudi Arabia.
Clinical Presentation and Successful Management of an Infant With Down Syndrome and COVID-19 in Riyadh, Saudi Arabia.
复制标题
DOI：
10.7759/cureus.13188
复制
发表时间：
2021-02-07
期刊：
影响因子：
--
通讯作者：
Alhamoud AH
中科院分区：
文献类型：
--
作者：
Alsahabi I;Alobaidi A;Alahmari AS;Almohsen N;Alhamoud AH
冠状病毒是一种严重的全球性疾病。唐氏综合征（DS）的特征是免疫失调，有各种解剖变异，并被认为是合并症。这些变异意味着，如果感染病毒，患有DS的儿童有患上严重COVID-19的风险。在这里，我们报告了第一例COVID-19病例，一名患有DS和先天性心脏病（CHD）的四个月大女婴在沙特阿拉伯利雅得第一卫生集群的Al-Imam Abdulrahman Al Faisal医院接受治疗。本文回顾此婴儿之医疗处理及临床结果。该名婴儿在接受其他医院的治疗后入院，病情恶化。患者出现皮疹，除基线药物（呋塞米和卡托普利）外，还需要氧气支持。入院后10天，患者病情改善，临床稳定。她在连续两次鼻咽拭子阴性后出院。根据报告的病例，DS和CHD婴儿应被视为COVID-19感染的高风险患者，需要密切观察。
Coronavirus is a serious, global disease. Down syndrome (DS) is characterized by immune dysregulation, has various anatomical variations, and is considered as comorbidity. These variations mean that children with DS are at risk of developing a severe case of COVID-19 if the virus is contracted. Here, we report the first case of COVID-19 in a four-month-old infant girl with DS and congenital heart disease (CHD) who was treated in Al-Imam Abdulrahman Al Faisal Hospital in the first health cluster in Riyadh, Saudi Arabia. The medical management and clinical outcome of the infant are reviewed. The infant was admitted after having received previous treatment from other hospitals, with a deteriorating condition. The patient had developed a rash, and oxygen support was required in addition to her baseline medication (furosemide and captopril). Ten days post admission, the patient’s condition improved, and she became clinically stable. She was then discharged after two consecutive negative nasopharyngeal swabs. Based on the reported case, infants with DS and CHD should be considered a high-risk patient in terms of COVID-19 infection and require close observation.
登录
查看更多内容
DOI：
10.1183/16000617.0098-2016
发表时间：
2017-01
期刊：
European respiratory review : an official journal of the European Respiratory Society
影响因子：
--
作者：
通讯作者：
--
影响因子：
3.4
作者：
Nisihara, Renato M.;Skare, Thelma L.;Utiyama, Shirley R. R.
通讯作者：
Utiyama, Shirley R. R.
影响因子：
9
作者：
Channappanavar R;Perlman S
通讯作者：
Perlman S
影响因子：
5.1
作者：
Stagliano, David R.;Nylund, Cade M.;Eberly, Matthew D.
通讯作者：
Eberly, Matthew D.
影响因子：
158.5
作者：
Guan, W.;Ni, Z.;Zhong, N.
通讯作者：
Zhong, N.